Drug-Eluting Stent

SAN FRANCISCO — Magnesium-based bioresorbable scaffolds resulted in a greater capacity of vasomotor response to pharmacological agents compared with sirolimus-eluting stents among patients with STEMI, according to 1-year follow-up data from the MAGSTEMI trial presented at TCT 2019.

PARIS — Biodegradable polymer sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with regard to target lesion failure among patients with STEMI who underwent PCI, according to 1-year results of the BIOSTEMI trial presented at the European Society of Cardiology Congress.

Whether you attended the European Society of Cardiology Congress in person or followed from afar, Cardiology Today and Healio have you covered.

Orchestra BioMed Inc., in partnership with Terumo Corporation, announced its sirolimus-eluting balloon for the treatment of below-the-knee peripheral artery disease, has received breakthrough device designation from the FDA.

Healio compiled a list of the most-read cardiac and vascular intervention articles in August. This month, our readers were interested in the FDA approval of transcatheter aortic valve replacement devices for use in patients at low surgical risk, FDA recommendations on the signal of late mortality risk associated with paclitaxel-coated devices, the benefits of antiplatelet therapy in patients with atrial fibrillation who had TAVR and much more.

PARIS — Ten-year follow-up data from the SYNTAXES trial highlight no significant difference in all-cause death among patients who underwent PCI using first-generation paclitaxel-eluting stents or CABG.

PARIS — Ticagrelor added to low-dose aspirin reduced the incidence of ischemic events in patients with stable CAD and diabetes without a history of MI or stroke, but increased major bleeding compared with aspirin alone, according to results of the THEMIS trial presented at the European Society of Cardiology Congress.

Comparison of a drug-eluting stent with a bare-metal stent in patients with CAD who were at high risk for bleeding.

Among patients who had endovascular revascularization of the superficial femoral artery, stent thrombosis occurred in more than 7% of patients, with a 5-year probability of more than 13%, researchers reported.

Drug-coated balloons were noninferior but not superior to drug-eluting stents for treatment of femoropopliteal lesions in high-risk patients with complex peripheral artery disease, according to the results of the DRASTICO study.